| Document |
Document Title |
|
JP2011506485A |
This invention relates to novel octahydroquinolizines for treatment or prevention of diabetes mellitus and its complications, for treatment or prevention of hyperlipidemia, for treatment of diabetic dyslipidemia, for treatment or prevent...
|
|
JP2011505363A |
The present invention provides novel alpha-fluoroalkyl compounds having structure I and the corresponding dihydrotetrabenazine compounds IV and intermediates useful in the preparation of such compounds. The alpha-fluoroalkyl compounds ar...
|
|
JP2011504493A |
The present invention relates to an organic electroluminescent compound and a display device using the same. The electroluminescent compound according to the present invention has good luminous efficiency and excellent lifetime of the ma...
|
|
JP4621356B2 |
Tricyclic quinolonecarboxylic acid derivatives represented by general formula (I) or salts thereof which are useful as remedies for skin infectious diseases, etc. showing a potent antibacterial effect on gram-positive and gram-negative b...
|
|
JP2011500678A |
The present invention is directed to spiropiperidine compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's...
|
|
JP4570857B2 |
A photosensitive composition containing: a sensitizing dye represented by the formula (1) as defined herein; an initiator compound capable of generating a radical, an acid, or a base; and a compound whose physical or chemical characteris...
|
|
JP4550072B2 |
A compound of formula (I) or a pharmaceutically acceptable salt or prodrug ester thereof: wherein the variants R, R9, Z, X, Q and Y are defined in the specification.
|
|
JP4492889B2 |
PCT No. PCT/US97/13723 Sec. 371 Date Oct. 23, 1998 Sec. 102(e) Date Oct. 23, 1998 PCT Filed Jul. 16, 1997 PCT Pub. No. WO98/04937 PCT Pub. Date Feb. 5, 1998The invention relates to photochromic compounds of general formula (I), in which:...
|
|
JP4489940B2 |
Novel compounds having formulas (I), (II) or (III) or pharmaceutically-acceptable salts or prodrugs thereof, which are useful for controlling synaptic transmission; to therapeutically-effective pharmaceutical compositions of these compou...
|
|
JP2010130912A |
To provide an efficient and industrial method for producing an optically active 3-quinuclidinol useful as an intermediate for medicines. The method for producing an optically active 3-quinuclidinol includes letting a microorganism capabl...
|
|
JP2010504919A |
The present invention provides 13,13a-dihydroberberine derivatives or their physiologically acceptable salts represented by the following formula, pharmaceutical compositions comprising the same, and uses thereof. The 13,13a-dihydroberbe...
|
|
JP4417627B2 |
The present invention provides compounds and compositions, including a selenonium or sulfonium group, which include; at least one chromophore having strong simultaneous two-photon or multi-photon absorptivity; at least one acid- or radic...
|
|
JP2010024239A |
To provide an inhibitor to enterokinesis aggravative action caused by nonsteroidal anti-inflammatory drugs, and to provide an antiinflammatory composition decreased in enterokinesis aggravating action.The inhibitor to enterokinesis aggra...
|
|
JP4404473B2 |
To provide compounds generating blue fluorescent luminescence with strong fluorescence intensity, materials for light emitting elements using those compounds, and light emitting elements having excellent purity of color. The materials fo...
|
|
JP4391421B2 |
There is provided an electroluminescent element using a material that is excellent in film forming properties and carrier transporting properties, emits a light in the solid state, and can be suitably used also as a host material. The el...
|
|
JP4376971B2 |
CFTR channel activator compounds from the benzo[c]quinolizinium family or families of compounds derived therefrom, as well as pharmaceutical compositions containing said compounds, and the uses thereof, particularly for treating cystic f...
|
|
JP4342797B2 |
This invention relates to new generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, to their optical isomers, diastereomers or enantiomers, as well as pharmaceut...
|
|
JPWO2007135970A1 |
The present invention has the formula (I).[During the ceremony, Ar1Indicates a triazolyl group or the like, which may be substituted with a C1-6 alkyl group or the like, and Ar2Indicates a phenyl group, etc., which may be substituted wit...
|
|
JP4333036B2 |
The present invention concerns derivatives of general formula I (I' and I''), in which X represents a divalent radical of formula (a) or (b), R1, R2, R3, and R4 represent, independently of each other, a hydrogen atom, a hydroxy radical, ...
|
|
JP4328049B2 |
A compound represented by the following Formula (I) or a pharmaceutically acceptable salt thereof: wherein R1 represents a hydrogen atom or a carboxyl-protecting group, R2 represents a hydrogen atom, a halogen atom, a lower alkyl group, ...
|
|
JP2009526795A |
The invention relates to aminoalcohol-substituted aryldihydroisoquinolinones and their derivatives, and their physiologically tolerated salts and physiologically functional derivatives, their preparation, medicaments comprising at least ...
|
|
JP4272262B2 |
This invention concerns compounds of formulathe pharmaceutically acceptable acid addition salts and the stereochemically isomeric forms thereof, wherein the dotted line represents an optional bond; X is oxygen or sulfur; -A- is a bivalen...
|
|
JP2009507855A |
This invention relates to novel compounds useful in the treatment of diseases associated with TRPV4 channel receptor. More specifically, this invention relates to certain acyclic diamines, which are agonists of TRPV4 channel receptors.
|
|
JP2009040789A |
To provide new compounds, a method for producing them and a medicinal composition containing them.A pleuromutilin derivative or its pharmaceutically acceptable salt is represented by formula (IA): wherein, n and m are each independently ...
|
|
JP2009035501A |
To provide a molecule converting light energy into unidirectional rotational energy at a molecular level (light-driven rotating molecule).The light-driven rotating molecule has a pigment site and a block unit which bind to a rotating sha...
|
|
JP4227729B2 |
Derivatives of pleuromutilin in which the glycolic ester moiety at position 14 is replaced by R 2 (CH 2 ) m X(CH 2 ) n CH 2 COO are of use in antimicrobial therapy. In which: each of n and m is independently 0, 1 or 2; X is selected from...
|
|
JP2009504599A |
The present invention refers to pharmaceutical composition comprising a DPP-IV inhibitor.
|
|
JP4219975B2 |
This invention relates to a process of the preparation of the novel intermediate (S)-4-fluoromethyl-dihydro-furan-2-one of the formula and with its use for the manufacture of pyrido[2,1-a]isoquinoline derivatives of the formula which are...
|
|
JP2009501202A |
The invention provides 3,11b- cis -dihydrotetrabenazine for use in halting or slowing the progress of one or more symptoms of Huntington's disease in a patient, and more particularly a symptom selected from involuntary movements such as ...
|
|
JP4204069B2 |
PCT No. PCT/EP97/04166 Sec. 371 Date Jan. 29, 1999 Sec. 102(e) Date Jan. 29, 1999 PCT Filed Jul. 29, 1997 PCT Pub. No. WO98/05659 PCT Pub. Date Feb. 12, 1998Compounds of formula (3), and pharmaceutically acceptable salts and derivatives ...
|
|
JP4197650B2 |
The present invention provides compounds of formula (I): wherein R1, R2, R3, R4, R5 and R6 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis ...
|
|
JP2008297278A |
To provide a low-molecular lysophosphatidic acid (LPA) receptor agonist and a prophylactic or therapeutic agent for various kinds of diseases caused by an LPA receptor, containing the agonist as an active ingredient.The LPA receptor agon...
|
|
JP4195615B2 |
A chromene compound typically represented by the following formula, When placed in a state of developing color, the chromene compound exhibits absorption bands in two wavelength regions of 440 to 500 nm and 570 to 630 nm. A difference in...
|
|
JP4183918B2 |
To provide a recording material, contained in an optical recording medium, which can be applied to a DVD-R disc system using a semiconductor laser having an oscillated wave length on the short wave length side, compared to a conventional...
|
|
JP4163254B2 |
PCT No. PCT/EP96/05874 Sec. 371 Date Dec. 4, 1998 Sec. 102(e) Date Dec. 4, 1998 PCT Filed Dec. 19, 1996 PCT Pub. No. WO97/25309 PCT Pub. Date Jul. 17, 1997Derivatives of mutiline of formula (1A) and pharmaceutically acceptable salts and ...
|
|
JP2008199009A |
To provide an organic electroluminescent device which is high in color purity and luminous efficiency, has a long lifetime and emits light in a red color system, and to provide a novel compound.The organic electroluminescent device inclu...
|
|
JP4137636B2 |
It was found that the compound having a binding activity to the cannabinoid type 2 receptor represented by the formula (I): wherein R' is a group represented by the formula: -Y<1>-Y<2>-Y<3>R wherein Y<1> is single bond or the like; Y<2> ...
|
|
JP4132155B2 |
|
|
JP4132461B2 |
|
|
JP2008169217A |
To provide a compound having the affinity for a cannabinoid type 2 receptor.There is provided a compound represented by formula (I) [wherein R1 is a group of the formula: -Y1-Y2-Y3-Ra (Y1 is a single bond or the like, Y2 is -C(=O)-NH- or...
|
|
JP2008524354A |
Cationic dissymmetrical diazo compounds (I), their resonance forms, acid addition salts an acid and/or their solvates are new. Cationic dissymmetrical diazo compounds of formula (I) (where electroneutrality of (I) is ensured by one or mo...
|
|
JP4105358B2 |
To obtain a blue-colored luminescent element (material) which may efficiently emit light with a high brightness at a low voltage drive, shows an excellent stability at repetitive use and has an excellent color purity. A benzimidazole der...
|
|
JP4101754B2 |
4-Oxoquinolizine derivatives (I) are new. 4-Oxoquinolizine derivatives of formula (I) and their salts are new. [Image] R1>H or carboxy protecting group; R2>H, halo, lower alkyl, lower alkoxy or OH; R3>phenyl or Het both optionally substi...
|
|
JP4096127B2 |
|
|
JP2008513382A |
Methods and compositions containing a berberine compound or berberine related or derivative compound are provided for the prevention and treatment of hyperlipidemia, elevated cholesterol, and/or cardiovascular disease in mammalian subjec...
|
|
JP4074509B2 |
The present invention relates to methods and intermediates for preparing compounds of the formula 1 and the pharmaceutically acceptable salts and solvates thereof, as well as structurally related compounds, wherein R<1>, R<2> and R<15> a...
|
|
JP2008509957A |
The invention relates to aryl-substituted polycyclic amines of formula I, especially bicyclic amines, and to the physiologically tolerated salts and physiologically functional derivatives thereof; where the symbols and radicals are expla...
|
|
JP4050939B2 |
To provide an organic electroluminescence device using fluorochrome with low driving voltage, solidity, and excellent light emitting efficiency. For the organic electroluminescence device having a substrate on which, an organic layer and...
|
|
JP4048780B2 |
Quinoline derivatives represented by formula (1) wherein two or more of substituents R1 to R7 are each a group of formula (2). It is preferable that among the substituents R1 to R7, at least one of the substituents other than those of ge...
|
|
JP4031705B2 |
The present invention relates generally to a process for recovering copper and other metal values from metal-containing materials using controlled, super-fine grinding and medium temperature pressure leaching. Processes embodying aspects...
|
